Saldaña-García MR, Saldaña-García C

Language: Spanish
References: 38
Page: 219-222
PDF size: 584.28 Kb.

ABSTRACT

The non-Hodgkin´s lymphomas (NHL) belong to a heterogeneous group of immune system neoplasms, the B type represents more than 90% of the cases. The rituximab (RTX) is a chimeric monoclonal antibody anti-CD20 (Human/mouse) created through Genetic engineering, which has been used with encouraging results on patients with relapse or refractory to low grade B-cell lymphoma treatment and with patients displaying a relapse on III/IV stages of follicular lymphoma. Its mechanisms of action is due to the apoptosis and the inhibition of transcriptional Map-kinase, p38, nuclear factor kappa-beta (NF-κ B) Sp-1, evolutionary related bcl-2 or YY1 are involved with the expression of the Fas ligand. The RTX is capable of inducing the complement dependant cytotoxicity and the antibody dependant cell cytotoxicity. Recently it is claimed its possible use in autoimmune diseases.

REFERENCES

1. Zelenetz A.D., et al., Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw. 9(5): p. 484-560.

2. Jaffe ES, et al, World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol, 1999. 111(1 Suppl 1): p. S8-12.

3. Vega MI, et al, Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005; 24(55): p. 8114-27.

4. Alexander DD, et al, The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer, 2007. 120 Suppl 12: p. 1-39.

5. INEGI, 2007.

6. Solís-Poblano JC, C.-d.A.M.d.l.L., Pegfilgrastim en el tratamiento del linfoma no Hodgkin. Informe sobre cinco casos. GAMO Vol. 9 Núm. 3, mayo – junio 201, 2010.

7. Fisher RI, et al, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 1993. 328(14): p. 1002-6.

8. Czuczman MS, et al, Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol, 2002. 29(1 Suppl 2): p. 36-40.

9. Mathe G, et al, BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease. Natl Cancer Inst Monogr, 1973. 39: p. 165-75.

10. Mathe G, et al, Follow-up of the first (1962) pilot study of active immunotherapy of acute lymphoid leukaemia: a critical discussion. Biomedicine, 1977. 26(1): p. 29-35.

11. Hernandez-Flores G, et al, In vitro induction of apoptosis in acute myelogenous and lymphoblastic leukemia cells by adriamycine is increased by pentoxifylline. Presse Med 39(12): p. 1330-1.

12. Dominguez-Rodriguez JR, et al, In vivo inhibition by antioxidants of adriamycin-induced apoptosis in murine peritoneal macrophages. Anticancer Res 2001. 21(3B): p. 1869-72.

13. Bravo-Cuellar A, et al, Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence. Mol Cancer. 9: p. 114.

14. Bravo-Cuellar A, et al, In vivo modification of adriamycin-induced apoptosis in L-5178Y lymphoma cell-bearing mice by (+)-alpha-tocopherol and superoxide dismutase. Cancer Lett, 2005. 229(1): p. 59-65.

15. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol, 2007. 35(4): p. 495-516.

16. Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci, 2004. 13(8): p. 1979-87.

17. Green DR and Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest, 2005. 115(10): p. 2610-7.

18. Ashwell JD, et al. Coming to terms with death: apoptosis in cancer and immune development. Immunol Today, 1994. 15(4): p. 147-51.

19. Kroemer G, et al, The biochemistry of programmed cell death. FASEB J, 1995. 9(13): p. 1277-87.

20. Packham G. and Stevenson Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology, 2005. 114(4): p. 441-9.

21. Schinoni MI, Parana R, and Cavalcante D. Apoptosis and progression of hepatic fibrosis in hepatitis C patients. Braz J Infect Dis, 2006. 10(2): p. 117-21.

22. Lawen A, Apoptosis-an introduction. Bioessays, 2003. 25(9): p. 888-96.

23. Vega MI, et al, Rituximab-mediated cell signaling and chemo/immunosensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res, 2009. 15(21): p. 6582-94.

24. Reff ME, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 1994. 83(2): p. 435-45.

25. Seymour JF. New treatment approaches to indolent non-Hodgkin's lymphoma. Semin Oncol, 2004. 31(1 Suppl 2): p. 27-32.

26. Czuczman MS, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 1999. 17(1): p. 268-76.

27. Stashenko P, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol, 1980. 125(4): p. 1678-85.

28. Tedder TF, McIntyre G, and Schlossman SF. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. Mol Immunol, 1988. 25(12): p. 1321-30.

29. Wines BD, et al, The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol, 2000. 164(10): p. 5313-8.

30. Vega MI, et al. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-Κ B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol, 2005. 175(4): p. 2174-83.

31. Vega MI, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene, 2004. 23(20): p. 3530-40.

32. Pedersen IM, et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood, 2002. 99(4): p. 1314-9.

33. Johnson P. and Glennie The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol, 2003. 30(1 Suppl 2): p. 3-8.

34. Sinha BK, et al. Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res, 1984. 44(7): p. 2892-6.

35. Maheo K, et al. Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med, 2005. 39(6): p. 742-51.

36. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int, 2008. 28(3): p. 205-15.

37. Linker RA, Kieseier BC, and Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci, 2008. 29(11): p. 558-65.

38. Waubant E, Spotlight on anti-CD20. Int MS J, 2008. 15(1): p. 19-25.